Table of Content

1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Oncology Companion Diagnostic Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product & Service (Product (Instrument, Consumables, Software), Service)
5.2.2. By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others)
5.2.3. By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others)
5.2.4. By End Use (Hospitals, Pathology/Diagnostic laboratory, Academic medical center)
5.2.5. By Region
5.2.6. By Company (2022)
5.3. Product Market Map
5.3.1. By Product & Service
5.3.2. By Technology
5.3.3. By Disease Type
5.3.4. By End Use
5.3.5. By Region
6. North America Oncology Companion Diagnostic Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product & Service (Product (Instrument, Consumables, Software), Service)
6.2.2. By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others)
6.2.3. By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others)
6.2.4. By End Use (Hospitals, Pathology/Diagnostic laboratory, Academic medical center)
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Oncology Companion Diagnostic Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product & Service
6.3.1.2.2. By Technology
6.3.1.2.3. By Disease Type
6.3.1.2.4. By End Use
6.3.2. Canada Oncology Companion Diagnostic Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product & Service
6.3.2.2.2. By Technology
6.3.2.2.3. By Disease Type
6.3.2.2.4. By End Use
6.3.3. Mexico Oncology Companion Diagnostic Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product & Service
6.3.3.2.2. By Technology
6.3.3.2.3. By Disease Type
6.3.3.2.4. By End Use
7. Europe Oncology Companion Diagnostic Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product & Service (Product (Instrument, Consumables, Software), Service)
7.2.2. By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others)
7.2.3. By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others)
7.2.4. By End Use (Hospitals, Pathology/Diagnostic laboratory, Academic medical center)
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Oncology Companion Diagnostic Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product & Service
7.3.1.2.2. By Technology
7.3.1.2.3. By Disease Type
7.3.1.2.4. By End Use
7.3.2. United Kingdom Oncology Companion Diagnostic Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product & Service
7.3.2.2.2. By Technology
7.3.2.2.3. By Disease Type
7.3.2.2.4. By End Use
7.3.3. France Oncology Companion Diagnostic Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product & Service
7.3.3.2.2. By Technology
7.3.3.2.3. By Disease Type
7.3.3.2.4. By End Use
7.3.4. Italy Oncology Companion Diagnostic Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product & Service
7.3.4.2.2. By Technology
7.3.4.2.3. By Disease Type
7.3.4.2.4. By End Use
7.3.5. Spain Oncology Companion Diagnostic Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product & Service
7.3.5.2.2. By Technology
7.3.5.2.3. By Disease Type
7.3.5.2.4. By End Use
8. Asia-Pacific Oncology Companion Diagnostic Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product & Service (Product (Instrument, Consumables, Software), Service)
8.2.2. By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others)
8.2.3. By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others)
8.2.4. By End Use (Hospitals, Pathology/Diagnostic laboratory, Academic medical center)
8.2.5. By Country
8.3. Asia-Pacific: Country Analysis
8.3.1. China Oncology Companion Diagnostic Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product & Service
8.3.1.2.2. By Technology
8.3.1.2.3. By Disease Type
8.3.1.2.4. By End Use
8.3.2. Japan Oncology Companion Diagnostic Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product & Service
8.3.2.2.2. By Technology
8.3.2.2.3. By Disease Type
8.3.2.2.4. By End Use
8.3.3. India Oncology Companion Diagnostic Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product & Service
8.3.3.2.2. By Technology
8.3.3.2.3. By Disease Type
8.3.3.2.4. By End Use
8.3.4. Australia Oncology Companion Diagnostic Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product & Service
8.3.4.2.2. By Technology
8.3.4.2.3. By Disease Type
8.3.4.2.4. By End Use
8.3.5. South Korea Oncology Companion Diagnostic Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product & Service
8.3.5.2.2. By Technology
8.3.5.2.3. By Disease Type
8.3.5.2.4. By End Use
9. South America Oncology Companion Diagnostic Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product & Service (Product (Instrument, Consumables, Software), Service)
9.2.2. By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others)
9.2.3. By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others)
9.2.4. By End Use (Hospitals, Pathology/Diagnostic laboratory, Academic medical center)
9.2.5. By Country
9.3. South America: Country Analysis
9.3.1. Brazil Oncology Companion Diagnostic Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product & Service
9.3.1.2.2. By Technology
9.3.1.2.3. By Disease Type
9.3.1.2.4. By End Use
9.3.2. Argentina Oncology Companion Diagnostic Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product & Service
9.3.2.2.2. By Technology
9.3.2.2.3. By Disease Type
9.3.2.2.4. By End Use
9.3.3. Colombia Oncology Companion Diagnostic Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product & Service
9.3.3.2.2. By Technology
9.3.3.2.3. By Disease Type
9.3.3.2.4. By End Use
10. Middle East and Africa Oncology Companion Diagnostic Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product & Service (Product (Instrument, Consumables, Software), Service)
10.2.2. By Technology (Polymerase chain reaction (PCR), Next-generation sequencing (NGS), Immunohistochemistry (IHC), In situ hybridization (ISH)/Fluorescence in situ hybridization (FISH), Others)
10.2.3. By Disease Type (Breast cancer, Non-small cell lung cancer, Colorectal cancer, Leukemia, Melanoma, Prostate cancer, Others)
10.2.4. By End Use (Hospitals, Pathology/Diagnostic laboratory, Academic medical center)
10.2.5. By Country
10.3. MEA: Country Analysis
10.3.1. South Africa Oncology Companion Diagnostic Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product & Service
10.3.1.2.2. By Technology
10.3.1.2.3. By Disease Type
10.3.1.2.4. By End Use
10.3.2. Saudi Arabia Oncology Companion Diagnostic Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product & Service
10.3.2.2.2. By Technology
10.3.2.2.3. By Disease Type
10.3.2.2.4. By End Use
10.3.3. UAE Oncology Companion Diagnostic Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product & Service
10.3.3.2.2. By Technology
10.3.3.2.3. By Disease Type
10.3.3.2.4. By End Use
10.3.4. Kuwait Oncology Companion Diagnostic Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Product & Service
10.3.4.2.2. By Technology
10.3.4.2.3. By Disease Type
10.3.4.2.4. By End Use
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Recent Development
12.2. Mergers & Acquisitions
12.3. Product Launches
13. Porter’s Five Forces Analysis
13.1. Competition in the Industry
13.2. Potential of New Entrants
13.3. Power of Suppliers
13.4. Power of Customers
13.5. Threat of Substitute Products
14. Competitive Landscape
14.1. Business Overview
14.2. Product Offerings
14.3. Recent Developments
14.4. Financials (As Reported)
14.5. Key Personnel
14.6. SWOT Analysis
14.6.1. Agilent Technologies Inc
14.6.2. Illumina Inc
14.6.3. QIAGEN NV
14.6.4. Thermo Fisher Scientific Inc
14.6.5. F Hoffmann-La Roche AG
14.6.6. ARUP Laboratories Inc
14.6.7. Abbott Laboratories Inc
14.6.8. Myriad Genetics Inc
14.6.9. bioM?rieux SA
14.6.10. Invivoscribe Inc
15. Strategic Recommendations
16. About Us & Disclaimer